Clinical trial · no report yet · Phase 3
ALKAZAR
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- NCT06765109 ↗
- Recruiting
- Nuvalent Inc.
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 7 | |
| X threads | 5 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer; Anaplastic Lymphoma Kinase-positive
- Interventions
- Neladalkib (NVL-655); Alectinib
- Arms
- Neladalkib (NVL-655) · Experimental
- Alectinib · Active comparator
- Enrollment
- 450 (estimated)
- Primary outcomes
- Progression-free survival (PFS) per blinded independent central review (BICR)
- Sponsor
- Nuvalent Inc.
- Start
- Jul 17, 2025
- Primary completion
- Dec 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06765109 · updated Sep 30, 2026